Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
103 hedge funds and large institutions have $74.5M invested in Evofem Biosciences, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 18 closing their positions.
72% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 18
63% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 19
11% more funds holding
Funds holding: 93 → 103 (+10)
7% less capital invested
Capital invested by funds: $80M → $74.5M (-$5.48M)
14% less call options, than puts
Call options by funds: $1.05M | Put options by funds: $1.22M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
+$8.33M |
| 2 |
CCM
CAAS Capital Management
New York
|
+$7.08M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$6.93M |
| 4 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
+$5.14M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$10.3M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$362K |
| 3 |
Squarepoint
New York
|
-$239K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$232K |
| 5 |
AC
Aristides Capital
Louisville,
Kentucky
|
-$222K |
EVFM Hedge Fund Activity: Q1 2021 in Review
103 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q1 2021, worth a combined $74.5M — down 6.8% from $80M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new EVFM positions and 18 closed out — a net gain of 13 holders — while 31 added to existing stakes and 19 trimmed.
The largest buyer was Maven Securities, opening a new position worth an estimated $8.33M. The largest seller was Invesco, cutting an estimated $10.3M.
- 103 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q1 2021, up from 93 in Q4 2020.
- Funds reported $74.5M of Evofem Biosciences, Inc. Common Stock stock for Q1 2021, down 6.8% quarter-over-quarter.
- 31 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q1 2021 and 18 closed out, a net change of +13 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q1 2021 was Maven Securities, an estimated $8.33M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q1 2021 was Invesco, an estimated $10.3M sold.
Based on aggregated 13F filings for Q1 2021.